Cell and gene therapy

This is the latest episode of the free DDW narrated podcast, “What’s at the forefront of innovation?” It covers three articles written for the for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Can animal genomics help find therapies for human disease?”, “Understanding and innovating in immunology”, and “Cell and gene […]

Moderna has reported encouraging interim data from its Phase I/II trial of mRNA-3927, an mRNA therapy for rare metabolic disorder propionic acidemia (PA). The data was presented at the 2023 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The ongoing global Phase I/II clinical trial is a multicentre, open-label study designed to assess […]

IB Communications’ CEO Michelle Boxall explains why there are two sides to the cell and gene therapy coin. Charles Dickens’ quote, “It was the best of times, it was the worst of times”, aptly describes the complexity surrounding CGT financing. With 2023’s financial outlook and predictions for the CGT market, there are two sides to […]

The US Food and Drug Administration (FDA) Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) have voted eight to six in favour of a new gene therapy for Duchenne muscular dystrophy. The vote supports the accelerated approval of Sarepta Therapeutics’ SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulatory patients with Duchenne muscular dystrophy with a […]

DDW’s Megan Thomas caught up with George White, General Manager, Product Management, Cell & Gene Therapy at Cytiva, to learn more about the company’s insight into the CGT market. Key challenges for cell and gene therapies In order for cell and gene (CGT) therapies to succeed, George White identifies several challenges to overcome. He says that […]

Ryan Leahy, a science communication expert in cell and gene therapy, at Phacilitate, says there is a lot to celebrate but also much to assess, question and challenge in this sector. While the global economic landscape faces a major crisis and biotech is not recession-proof, cell and gene therapy (CGT) has continued to progress with […]

This paid-for advertorial by Astrea Bioseparations appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 – Cell and Gene Therapy Guide. Therapeutic developers face significant challenges in purifying cell and gene therapy (CGT) modalities. Current processes rely on solutions developed for monoclonal antibodies that are not fit for purpose for viral vector purification, resulting […]

Cellular Origins, a company focused on enabling scalable and efficient manufacture of cell and gene therapies (CGTs), has announced a collaborative partnership with ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf that brings together process development expertise, tools and technologies for scalable CGT manufacturing.   The partnership aims to automate portions of […]

New South African company NewBiologix has launched with the aim of developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. The company’s DNA-based platform is being developed to address manufacturing challenges associated with the production of recombinant adeno-associated virus (rAAV) vectors used to produce […]

What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? DDW’s Megan Thomas finds out. Skills gap Bruce Levine, International Society for Cell & Gene Therapy (ISCT) Immediate Past President and Chair, Strategic Advisory Council, says a critical challenge that has become […]